{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-152309","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.158117+00:00","generated_at":"2026-06-01T06:48:53.531350+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Summit raises $200M, expands ivonescimab license to LAMEA regions","bullets":["Raised $200M via private placement of 22.2M shares at $9.00/share, a premium to the prior close.","Expanded ivonescimab license territory to Latin America, Middle East, Africa; $15M upfront plus up to $55M milestones.","Net proceeds will fund ivonescimab clinical development and general corporate purposes.","Registration rights agreement filed; resale registration statement expected within 60 days of closing.","Amendment strengthens data-sharing provisions for global ivonescimab trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-152309","json":"https://secwatch.observer/filing/0001193125-24-152309.json","markdown":"https://secwatch.observer/filing/0001193125-24-152309.md","text":"https://secwatch.observer/filing/0001193125-24-152309.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000119312524152309/0001193125-24-152309-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000119312524152309/d768276d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:48:53.531350+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}